Thoracic Endovascular Repair Shows Long-Term Success in Treating Aortic Injury
TEVAR Shows Promise for Long-Term Survival in Blunt Aortic Trauma Patients
A new study suggests that thoracic endovascular aortic repair (TEVAR) is an effective treatment for blunt traumatic aortic injury (BTAI), offering acceptable long-term survival rates and low reintervention needs.
The 20-year retrospective study, published in the European Journal of Vascular & Endovascular Surgery, analyzed data from 95 patients who underwent TEVAR for BTAI at four swedish trauma centers between 2001 and 2021. Researchers utilized data from the Swedish vascular and trauma registries, tracking patient outcomes for a median follow-up period of 6.1 years.
“Our findings demonstrate that TEVAR is a viable option for treating BTAI, with encouraging long-term survival rates,” said lead author victor Mill of Karolinska Institutet in stockholm, Sweden.
Promising Survival Rates and Low Reintervention Needs
The study revealed promising 5-year,10-year,and 15-year survival rates of 68%,64%,and 57%,respectively. While 16% of patients experienced 30-day mortality, the majority of thes deaths were attributed to traumatic brain injury (40%), followed by aortic-related causes (33%).
Reintervention rates, including procedures like restenting or graft explantation, remained relatively low at 16% within 18 months after the initial TEVAR procedure.
Procedural Complications and Management
While TEVAR proved largely triumphant, the study also highlighted potential procedural complications. Access-related issues,such as thrombosis,bleeding,and pseudoaneurysms,occurred in 10% of patients.
“It’s crucial to note that these complications were frequently enough manageable,” Mill explained. “only 11% of patients required open surgery, and 20% needed hemostatic adjuncts to control bleeding.”
Looking Ahead: future Research and Considerations
Despite the encouraging results, the study acknowledges limitations. The lack of a control group and the absence of data on nonoperative patients make it tough to directly compare TEVAR’s effectiveness to other treatment approaches.
The small sample size also limited the analysis of long-term effects like cardiac remodeling and hypertension.
Further research with larger, more diverse patient populations and comparative studies is needed to solidify TEVAR’s role as a standard treatment for BTAI.This study provides valuable insights into the long-term outcomes of TEVAR for BTAI, offering hope for improved survival rates and quality of life for patients suffering from this serious injury.
TEVAR Offers Hope for Long-Term Survival in Blunt Aortic Trauma Patients
Stockholm,Sweden – A groundbreaking new study published in the European Journal of Vascular & Endovascular surgery suggests that thoracic endovascular aortic repair (TEVAR) is a promising treatment for blunt traumatic aortic injury (BTAI),delivering encouraging long-term survival rates adn minimal reintervention needs.
This 20-year retrospective study, conducted by researchers at four Swedish trauma centers, analyzed data from 95 patients who underwent TEVAR for BTAI between 2001 and 2021.
“Our findings demonstrate that TEVAR is a viable option for treating BTAI, with encouraging long-term survival rates,” said lead author Victor Mill of Karolinska Institutet.
The study revealed impressive 5-year, 10-year, and 15-year survival rates of 68%, 64%, and 57%, respectively. Although 30-day mortality reached 16%,the majority of these deaths where attributed to traumatic brain injury (40%),followed by aortic-related causes (33%).
Reintervention rates, including procedures like restenting or graft explantation, remained low at 16% within 18 months after the initial TEVAR procedure. While procedural complications like thrombosis, bleeding, and pseudoaneurysms occurred in 10% of patients, Mill emphasized that “these complications were frequently manageable.” Only 11% of patients required open surgery, and 20% needed hemostatic adjuncts to control bleeding.
Despite the promising results, the study acknowledges limitations, including the lack of a control group and data on nonoperative patients. The small sample size also limited the analysis of long-term effects like cardiac remodeling and hypertension.
Further research with larger, more diverse patient populations and comparative studies is crucial to firmly establish TEVAR’s position as a standard treatment for BTAI.